Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood
Latest NewsView all
EryDel to Present its Phase 3 Study Results for Ataxia Telangiectasia ...
April 05, 2022Read more
EryDel’s Luca Benatti Discusses Red Blood Cell Infusion Biotech for Ataxia ...
March 08, 2022Read more
EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.Discover